Lisa Miller

Articles

Persistence Paved the Path of Discovery for an Immunotherapy Pioneer

October 8th 2018

Thomas F. Gajewski, MD, PhD, has made inroads in the field of cancer immunotherapy, most notably discovering the connections between the microbiome and clinical outcomes—findings that will enable the creation of microbiota-modulating interventions to improve outcomes in patients undergoing cancer treatments.

Debating the True Benefit of Adjuvant TKIs in High-Risk RCC

October 4th 2017

Adjuvant therapy with tyrosine kinase inhibitors for patients with high-risk renal cell carcinoma (RCC) who have undergone a nephrectomy may be supported by level IIa evidence from the National Comprehensive Cancer Network guidelines.

Proposed Changes to 340B May Curb Hospital Abuses

September 2nd 2017

Outpatient branded drug sales in the 340B Drug Pricing Program now amount to almost 8% of the total market, well up from 5.4% in 2012.

Identifying Actionable Biomarkers Crucial to Advancing Precision Medicine in MBC

July 28th 2017

While several biomarkers have been identified in patients with breast cancer, including ESR1 and PIK3CA mutations, not all of these are driver mutations that can be effectively targeted with treatment.

Trastuzumab Combos, Novel Agents Key to Advancing HER2+ Breast Cancer Care

July 28th 2017

Experts are trying to determine whether combination regimens with additional HER2-directed therapies or alternative therapies could improve responses in HER2-positive breast cancer without added toxicities.

Changes Planned for MPN Guidelines

May 26th 2017

The National Comprehensive Cancer Network published its first set of guidelines for myeloproliferative neoplasms in October 2016 and is already looking to update and expand these guidelines.

Expert Discusses Impact, Importance of Genetic Testing in Cancer

April 28th 2017

Howard A. “Skip” Burris III, MD, detailed the benefits of performing next-generation sequencing tests on patients with cancer at the 2017 Community Oncology Conference.

Immunotherapy Agents, Combinations to Compete for Frontline NSCLC

April 17th 2017

Sukhmani Padda, MD discusses the status of ongoing clinical trials participating in this race to the frontline setting in lung cancer.

Function of IDH Mutations Can Be Exploited by PARP Inhibitors Instead of IDH Inhibitors

April 4th 2017

A phase II basket trial has been announced to test that mutations in isocitrate dehydrogenase 1 and 2 are not driver mutations that should be targeted with direct IDH inhibitors, but instead they create vulnerabilities that can be exploited through treatment with PARP inhibitors.

Antibiotic Use May Damper the Efficacy of Checkpoint Inhibitors

February 14th 2017

Use of antibiotics up to a month before treatment with a checkpoint inhibitor may decrease the efficacy of the immunotherapy agent, results of a retrospective analysis show.

x